Correlation of Radiographic Progression with the Cumulative Activity of Synovitis Estimated by Power Doppler Ultrasound in Rheumatoid Arthritis: Difference Between Patients Treated with Methotrexate and Those Treated with Biological Agents
Identifieur interne : 000057 ( PascalFrancis/Checkpoint ); précédent : 000056; suivant : 000058Correlation of Radiographic Progression with the Cumulative Activity of Synovitis Estimated by Power Doppler Ultrasound in Rheumatoid Arthritis: Difference Between Patients Treated with Methotrexate and Those Treated with Biological Agents
Auteurs : Kei Ikeda [Japon] ; Daiki Nakagomi [Japon] ; Yoshie Sanayama [Japon] ; Mieko Yamagata [Japon] ; Ayako Okubo [Japon] ; Taro Iwamoto [Japon] ; Hirotoshi Kawashima [Japon] ; Kentaro Takahashi [Japon] ; Hiroshi Nakajima [Japon]Source :
- Journal of rheumatology [ 0315-162X ] ; 2013.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
Abstract
Objective. Our prospective study aimed to demonstrate that the cumulative synovial power Doppler (PD) ultrasound scores correlate with radiographic progression better than conventional measures in patients with rheumatoid arthritis (RA). We also investigated the difference between antirheumatic agents. Methods. Sixty-nine patients with RA who had recently received either methotrexate (MTX; n= 23), tumor necrosis factor (TNF) antagonists (n= 28), or tocilizumab (TCZ; n= 18) were enrolled. Patients underwent clinical, laboratory, and ultrasonographic assessment at baseline, 12 weeks, and 24 weeks. Radiographic damage was evaluated using van der Heijde modified total Sharp score (TSS) at baseline and 24 weeks. Results. Fifty-seven patients continued the same treatment regimen for 24 weeks and completed the study, and 21 patients (36.8%) showed radiographic progression during the study period. In all patients, ΔTSS significantly correlated both with cumulative 28-joint Disease Activity Score-C-reactive protein (DAS28-CRP; p= 0.342, p=0.009) and cumulative total PD scores (p= 0.357, p= 0.006). In MTX-treated patients, cumulative total PD scores significantly correlated with ΔTSS (p= 0.679, p= 0.004), whereas cumulative DAS28-CRP did not (p= 0.487, p= 0.056). However, cumulative total PD scores did not correlate with ΔTSS in TNF antagonist-treated or TCZ-treated patients. Conclusion. Our data confirm the evidence that synovial PD activity more accurately reflects active synovial inflammation (which actually causes joint destruction) than do conventional measures in patients treated with MTX. Our data also indicate that TNF antagonists can inhibit short-term radiographic progression in the presence of active synovitis.
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
Pascal:14-0028355Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Correlation of Radiographic Progression with the Cumulative Activity of Synovitis Estimated by Power Doppler Ultrasound in Rheumatoid Arthritis: Difference Between Patients Treated with Methotrexate and Those Treated with Biological Agents</title><author><name sortKey="Ikeda, Kei" sort="Ikeda, Kei" uniqKey="Ikeda K" first="Kei" last="Ikeda">Kei Ikeda</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Nakagomi, Daiki" sort="Nakagomi, Daiki" uniqKey="Nakagomi D" first="Daiki" last="Nakagomi">Daiki Nakagomi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Sanayama, Yoshie" sort="Sanayama, Yoshie" uniqKey="Sanayama Y" first="Yoshie" last="Sanayama">Yoshie Sanayama</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Yamagata, Mieko" sort="Yamagata, Mieko" uniqKey="Yamagata M" first="Mieko" last="Yamagata">Mieko Yamagata</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Okubo, Ayako" sort="Okubo, Ayako" uniqKey="Okubo A" first="Ayako" last="Okubo">Ayako Okubo</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Iwamoto, Taro" sort="Iwamoto, Taro" uniqKey="Iwamoto T" first="Taro" last="Iwamoto">Taro Iwamoto</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Kawashima, Hirotoshi" sort="Kawashima, Hirotoshi" uniqKey="Kawashima H" first="Hirotoshi" last="Kawashima">Hirotoshi Kawashima</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Takahashi, Kentaro" sort="Takahashi, Kentaro" uniqKey="Takahashi K" first="Kentaro" last="Takahashi">Kentaro Takahashi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Nakajima, Hiroshi" sort="Nakajima, Hiroshi" uniqKey="Nakajima H" first="Hiroshi" last="Nakajima">Hiroshi Nakajima</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0028355</idno><date when="2013">2013</date><idno type="stanalyst">PASCAL 14-0028355 INIST</idno><idno type="RBID">Pascal:14-0028355</idno><idno type="wicri:Area/PascalFrancis/Corpus">000032</idno><idno type="wicri:Area/PascalFrancis/Curation">000232</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000057</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000057</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Correlation of Radiographic Progression with the Cumulative Activity of Synovitis Estimated by Power Doppler Ultrasound in Rheumatoid Arthritis: Difference Between Patients Treated with Methotrexate and Those Treated with Biological Agents</title><author><name sortKey="Ikeda, Kei" sort="Ikeda, Kei" uniqKey="Ikeda K" first="Kei" last="Ikeda">Kei Ikeda</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Nakagomi, Daiki" sort="Nakagomi, Daiki" uniqKey="Nakagomi D" first="Daiki" last="Nakagomi">Daiki Nakagomi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Sanayama, Yoshie" sort="Sanayama, Yoshie" uniqKey="Sanayama Y" first="Yoshie" last="Sanayama">Yoshie Sanayama</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Yamagata, Mieko" sort="Yamagata, Mieko" uniqKey="Yamagata M" first="Mieko" last="Yamagata">Mieko Yamagata</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Okubo, Ayako" sort="Okubo, Ayako" uniqKey="Okubo A" first="Ayako" last="Okubo">Ayako Okubo</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Iwamoto, Taro" sort="Iwamoto, Taro" uniqKey="Iwamoto T" first="Taro" last="Iwamoto">Taro Iwamoto</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Kawashima, Hirotoshi" sort="Kawashima, Hirotoshi" uniqKey="Kawashima H" first="Hirotoshi" last="Kawashima">Hirotoshi Kawashima</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Takahashi, Kentaro" sort="Takahashi, Kentaro" uniqKey="Takahashi K" first="Kentaro" last="Takahashi">Kentaro Takahashi</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author><author><name sortKey="Nakajima, Hiroshi" sort="Nakajima, Hiroshi" uniqKey="Nakajima H" first="Hiroshi" last="Nakajima">Hiroshi Nakajima</name><affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>Japon</country><wicri:noRegion>Chiba</wicri:noRegion></affiliation></author></analytic><series><title level="j" type="main">Journal of rheumatology</title><title level="j" type="abbreviated">J. rheumatol.</title><idno type="ISSN">0315-162X</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of rheumatology</title><title level="j" type="abbreviated">J. rheumatol.</title><idno type="ISSN">0315-162X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term><term>Antirheumatic agent</term><term>Biological agent</term><term>Chronic</term><term>Doppler ultrasound study</term><term>Echography</term><term>Evolution</term><term>Human</term><term>Methotrexate</term><term>Prognosis</term><term>Radiography</term><term>Rheumatoid arthritis</term><term>Rheumatology</term><term>Synovitis</term><term>Treatment</term><term>Ultrasound</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Polyarthrite rhumatoïde</term><term>Radiographie</term><term>Evolution</term><term>Pronostic</term><term>Synovite</term><term>Dopplérométrie</term><term>Ultrason</term><term>Homme</term><term>Traitement</term><term>Méthotrexate</term><term>Agent biologique</term><term>Echographie</term><term>Rhumatologie</term><term>Chronique</term><term>Antirhumatismal</term><term>Anticancéreux</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective. Our prospective study aimed to demonstrate that the cumulative synovial power Doppler (PD) ultrasound scores correlate with radiographic progression better than conventional measures in patients with rheumatoid arthritis (RA). We also investigated the difference between antirheumatic agents. Methods. Sixty-nine patients with RA who had recently received either methotrexate (MTX; n= 23), tumor necrosis factor (TNF) antagonists (n= 28), or tocilizumab (TCZ; n= 18) were enrolled. Patients underwent clinical, laboratory, and ultrasonographic assessment at baseline, 12 weeks, and 24 weeks. Radiographic damage was evaluated using van der Heijde modified total Sharp score (TSS) at baseline and 24 weeks. Results. Fifty-seven patients continued the same treatment regimen for 24 weeks and completed the study, and 21 patients (36.8%) showed radiographic progression during the study period. In all patients, ΔTSS significantly correlated both with cumulative 28-joint Disease Activity Score-C-reactive protein (DAS28-CRP; p= 0.342, p=0.009) and cumulative total PD scores (p= 0.357, p= 0.006). In MTX-treated patients, cumulative total PD scores significantly correlated with ΔTSS (p= 0.679, p= 0.004), whereas cumulative DAS28-CRP did not (p= 0.487, p= 0.056). However, cumulative total PD scores did not correlate with ΔTSS in TNF antagonist-treated or TCZ-treated patients. Conclusion. Our data confirm the evidence that synovial PD activity more accurately reflects active synovial inflammation (which actually causes joint destruction) than do conventional measures in patients treated with MTX. Our data also indicate that TNF antagonists can inhibit short-term radiographic progression in the presence of active synovitis.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0315-162X</s0></fA01><fA02 i1="01"><s0>JRHUA9</s0></fA02><fA03 i2="1"><s0>J. rheumatol.</s0></fA03><fA05><s2>40</s2></fA05><fA06><s2>12</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Correlation of Radiographic Progression with the Cumulative Activity of Synovitis Estimated by Power Doppler Ultrasound in Rheumatoid Arthritis: Difference Between Patients Treated with Methotrexate and Those Treated with Biological Agents</s1></fA08><fA11 i1="01" i2="1"><s1>IKEDA (Kei)</s1></fA11><fA11 i1="02" i2="1"><s1>NAKAGOMI (Daiki)</s1></fA11><fA11 i1="03" i2="1"><s1>SANAYAMA (Yoshie)</s1></fA11><fA11 i1="04" i2="1"><s1>YAMAGATA (Mieko)</s1></fA11><fA11 i1="05" i2="1"><s1>OKUBO (Ayako)</s1></fA11><fA11 i1="06" i2="1"><s1>IWAMOTO (Taro)</s1></fA11><fA11 i1="07" i2="1"><s1>KAWASHIMA (Hirotoshi)</s1></fA11><fA11 i1="08" i2="1"><s1>TAKAHASHI (Kentaro)</s1></fA11><fA11 i1="09" i2="1"><s1>NAKAJIMA (Hiroshi)</s1></fA11><fA14 i1="01"><s1>Department of Allergy and Clinical Immunology, Chiba University Hospital</s1><s2>Chiba</s2><s3>JPN</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>9 aut.</sZ></fA14><fA20><s1>1967-1976</s1></fA20><fA21><s1>2013</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>16024</s2><s5>354000500731970080</s5></fA43><fA44><s0>0000</s0><s1>© 2014 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>39 ref.</s0></fA45><fA47 i1="01" i2="1"><s0>14-0028355</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Journal of rheumatology</s0></fA64><fA66 i1="01"><s0>CAN</s0></fA66><fC01 i1="01" l="ENG"><s0>Objective. Our prospective study aimed to demonstrate that the cumulative synovial power Doppler (PD) ultrasound scores correlate with radiographic progression better than conventional measures in patients with rheumatoid arthritis (RA). We also investigated the difference between antirheumatic agents. Methods. Sixty-nine patients with RA who had recently received either methotrexate (MTX; n= 23), tumor necrosis factor (TNF) antagonists (n= 28), or tocilizumab (TCZ; n= 18) were enrolled. Patients underwent clinical, laboratory, and ultrasonographic assessment at baseline, 12 weeks, and 24 weeks. Radiographic damage was evaluated using van der Heijde modified total Sharp score (TSS) at baseline and 24 weeks. Results. Fifty-seven patients continued the same treatment regimen for 24 weeks and completed the study, and 21 patients (36.8%) showed radiographic progression during the study period. In all patients, ΔTSS significantly correlated both with cumulative 28-joint Disease Activity Score-C-reactive protein (DAS28-CRP; p= 0.342, p=0.009) and cumulative total PD scores (p= 0.357, p= 0.006). In MTX-treated patients, cumulative total PD scores significantly correlated with ΔTSS (p= 0.679, p= 0.004), whereas cumulative DAS28-CRP did not (p= 0.487, p= 0.056). However, cumulative total PD scores did not correlate with ΔTSS in TNF antagonist-treated or TCZ-treated patients. Conclusion. Our data confirm the evidence that synovial PD activity more accurately reflects active synovial inflammation (which actually causes joint destruction) than do conventional measures in patients treated with MTX. Our data also indicate that TNF antagonists can inhibit short-term radiographic progression in the presence of active synovitis.</s0></fC01><fC02 i1="01" i2="X"><s0>002B15D</s0></fC02><fC02 i1="02" i2="X"><s0>002B24C01</s0></fC02><fC02 i1="03" i2="X"><s0>002B02L</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Polyarthrite rhumatoïde</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Rheumatoid arthritis</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Poliartritis reumatoidea</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Radiographie</s0><s5>04</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Radiography</s0><s5>04</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Radiografía</s0><s5>04</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Evolution</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Evolution</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Evolución</s0><s5>07</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Pronostic</s0><s5>08</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Prognosis</s0><s5>08</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Pronóstico</s0><s5>08</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Synovite</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Synovitis</s0><s5>09</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Sinovitis</s0><s5>09</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Dopplérométrie</s0><s5>13</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Doppler ultrasound study</s0><s5>13</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Dopplerometría</s0><s5>13</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Ultrason</s0><s5>14</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Ultrasound</s0><s5>14</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Ultrasonido</s0><s5>14</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0><s5>15</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Human</s0><s5>15</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0><s5>15</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Traitement</s0><s5>16</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Treatment</s0><s5>16</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Tratamiento</s0><s5>16</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Méthotrexate</s0><s2>NK</s2><s2>FR</s2><s5>17</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>Methotrexate</s0><s2>NK</s2><s2>FR</s2><s5>17</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Metotrexato</s0><s2>NK</s2><s2>FR</s2><s5>17</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Agent biologique</s0><s5>18</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>Biological agent</s0><s5>18</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>Agente biológico</s0><s5>18</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Echographie</s0><s5>19</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Echography</s0><s5>19</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Ecografía</s0><s5>19</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Rhumatologie</s0><s5>20</s5></fC03><fC03 i1="13" i2="X" l="ENG"><s0>Rheumatology</s0><s5>20</s5></fC03><fC03 i1="13" i2="X" l="SPA"><s0>Reumatología</s0><s5>20</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Chronique</s0><s5>30</s5></fC03><fC03 i1="14" i2="X" l="ENG"><s0>Chronic</s0><s5>30</s5></fC03><fC03 i1="14" i2="X" l="SPA"><s0>Crónico</s0><s5>30</s5></fC03><fC03 i1="15" i2="X" l="FRE"><s0>Antirhumatismal</s0><s5>31</s5></fC03><fC03 i1="15" i2="X" l="ENG"><s0>Antirheumatic agent</s0><s5>31</s5></fC03><fC03 i1="15" i2="X" l="SPA"><s0>Antireumático</s0><s5>31</s5></fC03><fC03 i1="16" i2="X" l="FRE"><s0>Anticancéreux</s0><s5>32</s5></fC03><fC03 i1="16" i2="X" l="ENG"><s0>Antineoplastic agent</s0><s5>32</s5></fC03><fC03 i1="16" i2="X" l="SPA"><s0>Anticanceroso</s0><s5>32</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Exploration ultrason</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Sonography</s0><s5>37</s5></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Exploración ultrasonido</s0><s5>37</s5></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Radiodiagnostic</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Radiodiagnosis</s0><s5>38</s5></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Radiodiagnóstico</s0><s5>38</s5></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Maladie autoimmune</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Autoimmune disease</s0><s5>39</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad autoinmune</s0><s5>39</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Rhumatisme inflammatoire</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Inflammatory joint disease</s0><s5>40</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Reumatismo inflamatorio</s0><s5>40</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du système ostéoarticulaire</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Diseases of the osteoarticular system</s0><s5>41</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Sistema osteoarticular patología</s0><s5>41</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Antifolate</s0><s5>42</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Antifolate</s0><s5>42</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Antifolato</s0><s5>42</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Antimétabolite</s0><s5>43</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Antimetabolic</s0><s5>43</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Antimetabólito</s0><s5>43</s5></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Immunopathologie</s0><s5>44</s5></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Immunopathology</s0><s5>44</s5></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Inmunopatología</s0><s5>44</s5></fC07><fN21><s1>027</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard></inist><affiliations><list><country><li>Japon</li></country></list><tree><country name="Japon"><noRegion><name sortKey="Ikeda, Kei" sort="Ikeda, Kei" uniqKey="Ikeda K" first="Kei" last="Ikeda">Kei Ikeda</name></noRegion><name sortKey="Iwamoto, Taro" sort="Iwamoto, Taro" uniqKey="Iwamoto T" first="Taro" last="Iwamoto">Taro Iwamoto</name><name sortKey="Kawashima, Hirotoshi" sort="Kawashima, Hirotoshi" uniqKey="Kawashima H" first="Hirotoshi" last="Kawashima">Hirotoshi Kawashima</name><name sortKey="Nakagomi, Daiki" sort="Nakagomi, Daiki" uniqKey="Nakagomi D" first="Daiki" last="Nakagomi">Daiki Nakagomi</name><name sortKey="Nakajima, Hiroshi" sort="Nakajima, Hiroshi" uniqKey="Nakajima H" first="Hiroshi" last="Nakajima">Hiroshi Nakajima</name><name sortKey="Okubo, Ayako" sort="Okubo, Ayako" uniqKey="Okubo A" first="Ayako" last="Okubo">Ayako Okubo</name><name sortKey="Sanayama, Yoshie" sort="Sanayama, Yoshie" uniqKey="Sanayama Y" first="Yoshie" last="Sanayama">Yoshie Sanayama</name><name sortKey="Takahashi, Kentaro" sort="Takahashi, Kentaro" uniqKey="Takahashi K" first="Kentaro" last="Takahashi">Kentaro Takahashi</name><name sortKey="Yamagata, Mieko" sort="Yamagata, Mieko" uniqKey="Yamagata M" first="Mieko" last="Yamagata">Mieko Yamagata</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PascalFrancis/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000057 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000057 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= TocilizumabV1
|flux= PascalFrancis
|étape= Checkpoint
|type= RBID
|clé= Pascal:14-0028355
|texte= Correlation of Radiographic Progression with the Cumulative Activity of Synovitis Estimated by Power Doppler Ultrasound in Rheumatoid Arthritis: Difference Between Patients Treated with Methotrexate and Those Treated with Biological Agents
}}
| This area was generated with Dilib version V0.6.34. |  |